5-Year Data on Secukinumab in AS; Oliceridine Not Recommended for FDA Approval
Mirtazapine Ineffective for Fibromyalgia
Central Sensitization to Pain May Not Predict Long-Term Outcomes after Carpal Tunnel Release Surgery
Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab
Pain Response to Low Intensity Pressure Tied to Cognitive Deficits in Fibromyalgia
The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials
Art Tours May Have Analgesic Effect for Chronic Pain Patients
Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray
- 1
- 2
- 3
- …
- 24
- Next Page »